Skip to content

Phase one clinical trials of hyperthermia using radiofrequency capacitive heating device and magnetic cationic liposome in prostate cancer resistant to standard treatment

Phase one clinical trials of hyperthermia using radiofrequency capacitive heating device and magnetic cationic liposome in prostate cancer resistant to standard treatment - Phase one clinical trials of hyperthermia using radiofrequency capacitive heating device

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000021187
Enrollment
3
Registered
2016-02-24
Start date
2014-07-04
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer

Interventions

injection of magnetite 30 mg of iron is contained by 1 ml of magnetite. Magnetite is injectied by 0.5ml into each four point of prostate. Magnetite is injected into prostate only once before warming

Sponsors

Nagoya City University Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: All patients had a histologically confirmed daignosis of prostate cancer Patients charactaristics. The treatment for prostate cancer is medication or radiation, not radical prostatectomy. The presence or absence of distant metastasis are not matter. Demonstrated evidence of recurrent prostatic cancer refractory to standard hormonal and anti cancer agnet therapy, including one or more hormonal drug, docetaxel, was required. Other eligibility criteria included the following: age over 20, under 80 years; Eastern Cooperative Oncology Group (EOCGI) performance status 0 to 2;

Exclusion criteria

Exclusion criteria: Exclusion criteria included the following: the patients who received radical prostatectomy; Case with metal reacting to the magnetic field in the body (Pacemaker, implant denture, iron clip bolt); patients with pleural effusion, ascitic fluid, the pericardial effusion which need urgent treatment; patients with active infection; patients with the multiple primary cancer with less than five years in disease-free interval; patients who communication is not possible; patients who is not suitable for local anesthesia; patients who has circulatory; during anticoagulation; patients of the diabetes mellitus inadequate control; the case that a chief physician judged to be unsuitable for subject of this study

Design outcomes

Primary

MeasureTime frame
Frequencies of adverse events grade 3 or more of CTCAE v4.0 Adverse events are evaluated at just after, 12 hours later, 24 hours later, one week later and on month later of injection of magnetite

Countries

Japan

Contacts

Public ContactNoriyasu Kawai

Nagoya City University Graduate School of Medical Sciences Department of Nephro-urology

n-kawai@med.nagoya-cu.ac.jp052-853-8266

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026